The Influence of Treatment Format on Schema Therapy for Borderline Personality Disorder
Launched by UNIVERSITY OF AMSTERDAM · Aug 3, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Schema Therapy (ST) for Borderline Personality Disorder (BPD) was originally developed and tested as an individual treatment. Since 2009 group-ST became popular as an supposedly efficient alternative. A RCT found combined individual-group ST to be superior to predominantly group-ST. Thus, individual ST is important. The question arises how combined individual-group ST compares to purely individual ST. This study compares the two formats of ST in a multicenter randomized clinical trial (RCT). The primary outcomes are severity of BPD and (early) treatment dropout. Secondary outcomes include: ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BPD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), assessed with the Structured Clinical Interview for the DSM-5 Personality Disorders (SCID-5-PD), as primary diagnosis
- • BPDSI total score ≥ 20 (i.e, severity in the BPD range, Giesen-Bloo et al., 2010)
- • Ability to understand, read, write and speak Dutch, or English if the site has research assistants and therapists of both conditions that are sufficiently fluent in English, as well as an English ST group (as at ACTP).
- Exclusion Criteria:
- • DSM-5 substance use disorder that needs clinical detox according to the clinical staff (after 6 weeks of abstinence participation is possible).
- • Comorbid psychotic disorder (patients with temporary psychotic problems falling under BPD criterion 9 are not excluded)
- • DSM-5 Bipolar disorder, type 1 (current or past)
- • Acute suicide risk
- • Intelligence Quotient (IQ) \< 80
- • Serious neurological problems such as dementia
- • Patients should not start with any form of psychological treatment during screening or during the study's waitlist or treatment. (Low frequency supportive treatment may be continued during wait and screening, but not during the study treatment.)
- • Not able or willing to plan participation in the treatment sessions. Note 1. In case of suspicion of exclusion criteria that need specific assessment, like IQ and dementia, a formal diagnostic assessment needs to be done before in/exclusion can be decided.
- • Note 2. No other psychological treatment during the study follow-up period is provided, unless this is necessary (clinical judgment). The 1 year treatment-free follow-up period is part of the treatment protocol, to help patients gain experience with life without mental health care. After 1 year further treatment can be offered, if indicated.
About University Of Amsterdam
The University of Amsterdam (UvA) is a leading research institution renowned for its commitment to advancing knowledge and fostering innovation in various fields, including health sciences. As a sponsor of clinical trials, UvA leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous research aimed at improving patient outcomes and understanding complex medical conditions. The university promotes ethical research practices and adheres to stringent regulatory standards, ensuring the integrity and reliability of its clinical studies. Through collaboration with healthcare professionals and industry partners, UvA strives to translate research findings into practical applications that benefit society and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Amsterdam, , Netherlands
Patients applied
Trial Officials
Arnoud Arntz, PhD
Principal Investigator
University of Amsterdam
Sophie Rameckers, MSc
Principal Investigator
University of Amsterdam
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported